Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navafenterol (AZD8871) in Asthma and COPD
NCT02573155Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2015
- Primary completion
- Aug 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of navafenterol in asthma and chronic obstructive pulmonary disease (COPD) (18 arms), sponsored by AstraZeneca. Primary endpoints: Number of Participants With Mild Persistent Asthma (Part 1) and COPD (Part 2) With at Least 1 Treatment-emergent Adverse Event, Number of Participants With Clinically Relevant Abnormalities in Blood Pressure and 3 more. Started Oct 2015; status: completed.
02
Drugs
navafenterol
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02573155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02573155.